All News

The DermaSensor skin cancer screening device was pitted against clinical impressions of lesions suspected with high confidence to be melanoma. Results, here.

Your daily dose of the clinical news you may have missed.

Dermatologists at high volume dermatology centers referred suspicious lesions to pathology for biopsy and diagnosis. The results were compared with DermaSensor read-outs.

ACAAI 2024. Two studies here showed that anaphylaxis protocols for EMS are outdated in many states and that many patients don't know how to use epinephrine.

Your daily dose of the clinical news you may have missed.

More than half of US adults who had a colonoscopy in past 5 years said they wish they knew more information before their first procedure.

Rifaximin monotherapy may also confer a survival benefit, according to the study, which was awarded ACG Outstanding Research Award in the Liver Category.

A rapid increase in the rate of melanoma diagnoses could be the result of multiple factors, explains the Harvard assistant professor of dermatology.

Oral sulopenem is the first oral penem approved in the US for treating uUTIs in women with limited options.

A summary of new data presented at the 2024 American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

After 60 months of treatment, 38% of study participants with severe AD achieved complete remission.

Semaglutide significantly reduced risk of a first-time diagnosis of AD in a cohort of more than 1 million, suggesting an opportunity for controlled clinical trials.

Your daily dose of the clinical news you may have missed.

A bothersome skin lesion is typically first seen and assessed in primary care. An AI-based point-of-care device may help enhance triage, says Rebecca Hartman, MD, MPH.

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

Your daily dose of the clinical news you may have missed.

The ACIP voted on recommendations for monovalent SARS-CoV-2 vaccine booster shots, lowering the age for pneumonia vaccination, and next steps for clesrovimab for RSV.

The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.